MOONLAKE IMMUNO (MLTX)
(Delayed Data from NSDQ)
$51.04 USD
+4.62 (9.95%)
Updated Sep 12, 2024 03:59 PM ET
After-Market: $51.02 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for MoonLake Immunotherapeutics falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 511 | 72 | 1 | 1 | -99,999 |
Receivables | 1 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 2 | 4 | 0 | 0 | NA |
Total Current Assets | 514 | 77 | 1 | 2 | NA |
Net Property & Equipment | 0 | 0 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 115 | 115 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 8 | 0 | 0 | 0 | NA |
Total Assets | 527 | 77 | 116 | 117 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 2 | 0 | 0 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 7 | 7 | 4 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 10 | 8 | 4 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 4 | 4 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 1 | 0 | 115 | 107 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 13 | 8 | 123 | 112 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 610 | 129 | 0 | 5 | NA |
Retained Earnings | -117 | -81 | -7 | 0 | NA |
Other Equity | 20 | 20 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 513 | 69 | -7 | 5 | NA |
Total Liabilities & Shareholder's Equity | 527 | 77 | 116 | 117 | NA |
Total Common Equity | 513 | 69 | -7 | 5 | 0 |
Shares Outstanding | 62.90 | 52.70 | 3.30 | 11.90 | NA |
Book Value Per Share | 8.16 | 1.30 | -2.14 | 0.42 | 0.00 |
Fiscal Year End for MoonLake Immunotherapeutics falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 520 | 547 | 511 | 496 | 502 |
Receivables | 2 | 2 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 15 | 5 | 2 | 3 | 4 |
Total Current Assets | 537 | 554 | 514 | 500 | 506 |
Net Property & Equipment | 0 | 1 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 6 | 8 | 0 | 0 |
Total Assets | 545 | 564 | 527 | 500 | 507 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 3 | 2 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 4 | 7 | 7 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 12 | 9 | 10 | 10 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 15 | 12 | 13 | 11 | 8 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 672 | 670 | 610 | 531 | 590 |
Retained Earnings | -155 | -130 | -117 | -109 | -100 |
Other Equity | 13 | 13 | 20 | 68 | 9 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 530 | 552 | 513 | 490 | 499 |
Total Liabilities & Shareholder's Equity | 545 | 564 | 527 | 500 | 507 |
Total Common Equity | 530 | 552 | 513 | 490 | 499 |
Shares Outstanding | 63.80 | 63.80 | 62.90 | 62.40 | 62.40 |
Book Value Per Share | 8.31 | 8.66 | 8.16 | 7.85 | 8.00 |